Sedana Medical AB (SEDANA) AI Stock Analysis

• Market Cap: kr1.08B
• Dividend Yield: N/A
• Average Volume (3M): 302.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: 13.66%
• EPS Growth: -139.90%
• Country: SE
• Employees: 113
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): -0.24
• Shares Outstanding: 99,336,960
• 10 Day Avg. Volume: 216,068
• 30 Day Avg. Volume: 302,145
• PEG Ratio: -1.31
• Price to Book (P/B): 1.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: kr11.50 ▲(5.50%Upside)

The overall stock score is primarily influenced by the financial performance, which highlights strong revenue growth but is hindered by negative profitability and cash flow challenges. The technical analysis suggests a neutral trend, and the valuation remains a concern due to the negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Sedana Medical AB Business Overview & Revenue Model

Company Description

Sedana Medical AB (SEDANA) is a Swedish medical technology company that specializes in developing, marketing, and selling medical devices and pharmaceuticals for inhalation sedation. Sedana Medical's core product is the AnaConDa, a system designed to administer volatile anesthetics for sedation in intensive care units. The company operates primarily within the healthcare sector, focusing on providing innovative solutions to improve patient care and outcomes in critical care settings.

How the Company Makes Money

Sedana Medical makes money primarily through the sales of its AnaConDa system and related consumables. The AnaConDa system is sold to hospitals and healthcare facilities, where it is used for sedating patients in intensive care units. Revenue is generated from both the initial sale of the AnaConDa device and the recurring sales of consumables required for its operation. Sedana Medical may also generate revenue through partnerships and collaborations with healthcare providers and distributors, as well as through potential licensing agreements for its technology.

Sedana Medical AB Financial Statement Overview

Summary

Sedana Medical demonstrates strong revenue growth and a robust balance sheet with low leverage. However, the company faces challenges with persistent negative margins and cash flow, indicating ongoing operational inefficiencies. Significant improvements in profitability and cash flow generation are necessary for better financial health.

Income Statement

Sedana Medical's revenue has shown a steady increase over the years, with a notable revenue growth rate of 30.1% in the TTM (Trailing-Twelve-Months) compared to 2022. However, the company continues to experience negative profitability with a net profit margin of -29.2% and an EBIT margin of -25.3% in the TTM. These persistent losses indicate ongoing challenges in achieving operational efficiency and profitability.

Balance Sheet

The company maintains a strong equity position, with an equity ratio of 93.9% in the TTM, indicating financial stability. The debt-to-equity ratio is low at 0.005, reflecting minimal leverage and reduced financial risk. However, the ongoing operational losses impact return on equity, which remains negative.

Cash Flow

Free cash flow remains negative, though it improved slightly in the TTM with a growth rate of 17.7% compared to 2024. The operating cash flow to net income ratio is negative, indicating the company is not generating sufficient cash from operations to cover its net losses. This highlights a need for improved cash management and operational efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	187.43M	178.75M	153.87M	122.86M	159.15M	141.77M
Gross Profit	132.03M	126.14M	108.98M	86.07M	106.71M	88.90M
EBITDA	-26.58M	-29.17M	-51.67M	-64.87M	-49.10M	-17.22M
Net Income	-54.77M	-10.67M	-59.61M	-73.51M	-57.97M	-27.14M
Balance Sheet
Total Assets	995.55M	1.02B	1.01B	1.08B	1.17B	600.10M
Cash, Cash Equivalents and Short-Term Investments	165.13M	193.96M	381.80M	607.74M	836.18M	376.17M
Total Debt	4.88M	5.92M	4.31M	8.74M	8.87M	8.29M
Total Liabilities	60.65M	61.17M	44.06M	52.43M	66.12M	49.00M
Stockholders Equity	934.90M	958.23M	970.00M	1.03B	1.10B	551.09M
Cash Flow
Free Cash Flow	-153.86M	-186.77M	-206.95M	-253.22M	-151.48M	-92.47M
Operating Cash Flow	-14.10M	-11.77M	-38.06M	-115.43M	-41.22M	-7.85M
Investing Cash Flow	-165.39M	-44.67M	-321.96M	-137.78M	-110.25M	-84.62M
Financing Cash Flow	-3.33M	-3.57M	-4.86M	-1.51M	605.07M	5.79M

Sedana Medical AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Negative. The current price of 10.9 is below the 20-day moving average (MA) of 11.10, below the 50-day MA of 11.26, and below the 200-day MA of 15.20, indicating a bearish trend. The MACD of -0.38 indicates Positive momentum. The RSI at 47.08 is Neutral, neither overbought nor oversold. The STOCH value of 80.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SEDANA.

Sedana Medical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	kr1.22B	37.62	10.11%	―	2.53%	-44.90%
SEDANA	55 Neutral	kr1.08B	―	-5.61%	―	13.66%	-139.90%
INTEG.B	53 Neutral	kr424.98M	―	-19.17%	―	-12.50%	-783.92%
Sector *	50 Neutral	kr5.29B	11.97	-82.66%	9.67%	36.04%	27.80%
ACARIX	46 Neutral	kr361.67M	―	-88.97%	―	-0.61%	54.19%
BACTI.B	46 Neutral	kr1.02B	―	-7.30%	―	23.51%	80.47%
MNTC	45 Neutral	€345.18M	―	-17.16%	―	17.75%	18.05%

Sedana Medical AB Corporate Events

Sedana Medical’s US Studies Achieve Key Endpoint in Opioid Reduction

Sedana Medical AB announced that its pivotal US studies, INSPiRE-ICU 1 and 2, have successfully met a key secondary endpoint by demonstrating a significant reduction in opioid doses compared to the control group. This achievement supports the company’s aim for US registration of its Sedaconda ACD device and isoflurane for ICU sedation, potentially impacting the US market by providing an alternative to opioid use. The results, which align with previous European studies, will be crucial for the FDA’s assessment of Sedana Medical’s marketing authorization application.

Sedana Medical AB Annual General Meeting Highlights Key Resolutions

Sedana Medical AB held its annual general meeting on May 15, 2025, where key resolutions were passed, including the adoption of financial statements for 2024 and the decision not to distribute dividends. The meeting also approved the re-election of board members and auditors, and authorized the board to issue new shares. A performance-based incentive program for employees was introduced, aimed at aligning staff interests with company growth, potentially impacting employee motivation and shareholder value.

Sedana Medical Reports Record Quarter with Strong Sales Growth

Sedana Medical AB reported a record quarter with net sales increasing by 18% compared to the same period in 2024, driven by its focus on inhaled sedation products. Despite facing negative currency effects, the company showed improved financial performance with a reduced EBITDA loss and positive cash flow from operating activities, highlighting its strong market positioning and operational resilience.